SkinBioTherapeutics plc's ordinary shares started trading on the London Stock Exchange's AIM market on April 5 under the ticker SBTX.
The company's IPO raised £4.5 million in gross proceeds with the issuance of 118,708,494 ordinary shares at 9 pence per share, including a cornerstone investment from U.K. equity investor Seneca Partners Ltd.
Estimated net proceeds from the offering were £4.1 million.
Cairn Financial Advisers LLP was the nominated adviser for the IPO and Turner Pope Investments Ltd. acted as the broker.
OptiBiotix Health PLC holds a significant stake in SkinBioTherapeutics.